Recombinant Antibodies

Datopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and

Datopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and

Datopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and

Daxdilimab (anti-ILT7) is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab (anti-ILT7) can be used in acute lung injury (ALI) in patients with COVID-19 infection

Demcizumab (anti-DLL4) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab (anti-DLL4) alone or in combination with chemotherapy is effective in various cancer models.Purity&gt95%

Demcizumab (anti-DLL4) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab (anti-DLL4) alone or in combination with chemotherapy is effective in various cancer models.Purity&gt95%

Demcizumab (anti-DLL4) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab (anti-DLL4) alone or in combination with chemotherapy is effective in various cancer models.Purity&gt95%

Demcizumab (anti-DLL4) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab (anti-DLL4) alone or in combination with chemotherapy is effective in various cancer models.Purity&gt95%

Dog IgG Antibody Isotype Control Antibody

Dog IgG Antibody Isotype Control Antibody

Dog IgG Antibody Isotype Control Antibody

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement